Hexiris Ophthalmics, based in Dieppe, New Brunswick, is making significant strides towards the commercial launch of its innovative glaucoma treatment technologies, scheduled for later in 2026. The company announced its participation in the Canadian Ophthalmological Society (COS) Annual Meeting in Montreal, Quebec, where it will provide surgeons with hands-on experience of its products, OBi Core and OBi Gon, through a dedicated dry lab session. This initiative aligns with the growing trend of office-based surgeries, which have shown to reduce patient costs by 30 to 50% without compromising safety. With approximately 80 million people worldwide affected by glaucoma, Hexiris aims to address the critical access issues that prevent effective treatment for many patients. The company has also launched a new website and social media presence to better connect with surgeons and stakeholders, emphasizing its commitment to expanding access to interventional glaucoma care. Founded by Dr. Houfar Sekhavat and Dr. Nir Shoham-Hazon, Hexiris is dedicated to simplifying glaucoma treatment through innovative devices, with OBi Core already approved by Health Canada and registered with the FDA.